OptimizeRx price target raised to $14 from $11 at Citizens JMP

Citizens JMP analyst Constantine Davides raised the firm’s price target on OptimizeRx (OPRX) to $14 from $11 and keeps an Outperform rating on the shares following the Q1 earnings report. Management raised 2025 revenue guidance from its prior $100M minimum, to $101M-$106M, the analyst tells investors in a research note. The firm believes that a higher multiple as warranted given OptimizeRx’s double-digit organic growth rate, improved revenue visibility, and expanding operating leverage.